The Benevolent Platform™ drives two revenue streams. Our business model offers multiple routes for revenue generation and value creation.

Established business

End-to-end drug discovery

Drug discovery offerings

  • Platform enables novel discoveries throughout the drug discovery process
  • Continuing to expand on our industry-leading collaborations
  • Validated by collaborations with AstraZeneca and Merck

High value collaborations

Upfront payments + milestones + royalties

Preclinical and clinical development pipeline

Platform generated assets

  • Five high potential assets
  • Potentially first-in-class or best-in-class assets providing novel therapeutic opportunities
  • Progressing assets to significant inflection points

Mid to long-term value creation

Upfront fees + milestones + royalties


Reach your full research and development potential.

Speak to our business development team.

Contact us

Hear more about investment opportunities.

Speak to our investor relations team

Contact us